On November 16, 2023 HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, reported its participation at the World Vaccine Congress West Coast 2023 in Santa Clara, California, from November 27 through 30, 2023 (Press release, HDT Bio, NOV 16, 2023, https://www.prnewswire.com/news-releases/hdt-bio-to-participate-in-world-vaccine-congress-west-coast-2023-301990457.html [SID1234637745]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
HDT Bio’s AMPLIFY vaccine platform combines repRNA coding for an antigen target and LION formulation technology to provide a versatile solution for a range of pathologies, from infectious diseases to cancer. The platform offers increased safety and potency, simplified manufacturing, and improved temperature stability compared to traditional RNA vaccines, allowing for increased efficacy with the potential for multivalency.
Steven Reed, Ph.D., Chief Executive Officer of HDT Bio will moderate a panel entitled, "SupeRNAtural: Realizing the potential of RNA therapeutics for ID & Cancer," on Wednesday, November 29, at 10:15 a.m. PT in Hall B. Panel participants include Zelanna Goldberg, M.D., Chief Medical Officer of Replicate Bioscience, Inc., Robert Shoemaker, Ph.D., Co-Chief of Chemopreventive Agent Development at the National Cancer Institute, and Joshua DiNapoli, Ph.D., Global Project Head mRNA Platform of Sanofi. The panel will discuss the wide variety of RNA molecules used to inhibit infectious diseases and cancer, along with common challenges within the field.
Dr. Steven Reed will also deliver a presentation entitled, "AMPLIFY Vaccine Platform: repRNA + LION," as part of the Cancer and Immunotherapy portion of the conference on Wednesday, November 29, at 1:05 p.m. PT. HDT Bio’s AMPLIFY platform is designed to enhance flexibility of manufacturing, improve stability during storage, while increasing cellular immune responses.
Additionally, Darrick Carter, Ph.D., Co-Founder and Senior Advisor of HDT Bio, will deliver a presentation entitled, "JO – opening tumor junctions to treat cancer" as part of the Immune Profiling session, on Wednesday, November 29, at 3:30 p.m. PT.
"The World Vaccine Congress West Coast 2023 has evolved into an impactful and influential platform, seamlessly integrating advancements in cancer and infectious disease research, bringing together innovative minds in the field of vaccines and immunology. At HDT Bio, we’re dedicated to pioneering solutions for infectious diseases and cancer, and we believe that the future of preventive healthcare lies in the potential of RNA technologies." commented Dr. Steven Reed, CEO of HDT Bio. "We look forward to sharing our insights, exchange ideas, and collaborate with the brilliant minds gathered at this conference, as well as highlighting the advances of our AMPLIFY vaccine platform, and our ACCESS junction opener technology designed to improve tumor penetrance."